vs
iSpecimen Inc.（ISPC）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是iSpecimen Inc.的13686.9倍（$708.5M vs $51.8K）。Medpace Holdings, Inc.净利率更高（19.1% vs -9662.2%，领先9681.3%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -96.5%）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -85.0%）
Specimen Products是一家总部位于芝加哥的乐器与音响设备制造商，由制琴师伊恩·施纳勒创立，主打定制吉他、电子管功放与号角音箱产品。品牌还依托旗下芝加哥吉他制作学院开设吉他、电子管功放的设计、制作与维修课程，工坊也面向公众提供设备维修服务，可调用稀有 vintage 厂商的零件储备开展维修。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
ISPC vs MEDP — 直观对比
营收规模更大
MEDP
是对方的13686.9倍
$51.8K
营收增速更快
MEDP
高出128.5%
-96.5%
净利率更高
MEDP
高出9681.3%
-9662.2%
两年增速更快
MEDP
近两年复合增速
-85.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $51.8K | $708.5M |
| 净利润 | $-5.0M | $135.1M |
| 毛利率 | -964.4% | — |
| 营业利润率 | -5192.9% | 21.6% |
| 净利率 | -9662.2% | 19.1% |
| 营收同比 | -96.5% | 32.0% |
| 净利润同比 | 17.3% | 15.5% |
| 每股收益（稀释后） | $-0.67 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISPCMEDP
| Q4 25 | $51.8K | $708.5M | ||
| Q3 25 | $106.6K | $659.9M | ||
| Q2 25 | $713.1K | $603.3M | ||
| Q1 25 | $1.1M | $558.6M | ||
| Q4 24 | $1.5M | $536.6M | ||
| Q3 24 | $2.7M | $533.3M | ||
| Q2 24 | $2.9M | $528.1M | ||
| Q1 24 | $2.3M | $511.0M |
净利润ISPCMEDP
| Q4 25 | $-5.0M | $135.1M | ||
| Q3 25 | $-2.8M | $111.1M | ||
| Q2 25 | $-1.0M | $90.3M | ||
| Q1 25 | $-1.7M | $114.6M | ||
| Q4 24 | $-6.0M | $117.0M | ||
| Q3 24 | $-1.4M | $96.4M | ||
| Q2 24 | $-2.1M | $88.4M | ||
| Q1 24 | $-2.9M | $102.6M |
毛利率ISPCMEDP
| Q4 25 | -964.4% | — | ||
| Q3 25 | -47.0% | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 42.4% | — | ||
| Q4 24 | 13.5% | — | ||
| Q3 24 | 43.4% | — | ||
| Q2 24 | 51.9% | — | ||
| Q1 24 | 58.4% | — |
营业利润率ISPCMEDP
| Q4 25 | -5192.9% | 21.6% | ||
| Q3 25 | -2655.2% | 21.5% | ||
| Q2 25 | -255.4% | 20.9% | ||
| Q1 25 | -154.9% | 20.3% | ||
| Q4 24 | -395.8% | 23.4% | ||
| Q3 24 | -64.1% | 21.1% | ||
| Q2 24 | -76.2% | 19.9% | ||
| Q1 24 | -131.0% | 20.4% |
净利率ISPCMEDP
| Q4 25 | -9662.2% | 19.1% | ||
| Q3 25 | -2608.7% | 16.8% | ||
| Q2 25 | -146.9% | 15.0% | ||
| Q1 25 | -156.8% | 20.5% | ||
| Q4 24 | -409.8% | 21.8% | ||
| Q3 24 | -54.1% | 18.1% | ||
| Q2 24 | -73.6% | 16.7% | ||
| Q1 24 | -126.7% | 20.1% |
每股收益（稀释后）ISPCMEDP
| Q4 25 | $-0.67 | $4.65 | ||
| Q3 25 | $-0.48 | $3.86 | ||
| Q2 25 | $-0.42 | $3.10 | ||
| Q1 25 | $-0.71 | $3.67 | ||
| Q4 24 | $-5.40 | $3.67 | ||
| Q3 24 | $-2.10 | $3.01 | ||
| Q2 24 | $-3.72 | $2.75 | ||
| Q1 24 | $-6.36 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.9M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.1M | $459.1M |
| 总资产 | $9.5M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ISPCMEDP
| Q4 25 | $6.9M | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | $1.9M | $669.4M | ||
| Q3 24 | $1.8M | $656.9M | ||
| Q2 24 | $2.2M | $510.9M | ||
| Q1 24 | $2.1M | $407.0M |
股东权益ISPCMEDP
| Q4 25 | $3.1M | $459.1M | ||
| Q3 25 | $3.1M | $293.6M | ||
| Q2 25 | $622.0K | $172.4M | ||
| Q1 25 | $1.7M | $593.6M | ||
| Q4 24 | $3.3M | $825.5M | ||
| Q3 24 | $4.7M | $881.4M | ||
| Q2 24 | $6.1M | $763.6M | ||
| Q1 24 | $6.8M | $671.5M |
总资产ISPCMEDP
| Q4 25 | $9.5M | $2.0B | ||
| Q3 25 | $9.0M | $1.8B | ||
| Q2 25 | $6.0M | $1.6B | ||
| Q1 25 | $6.8M | $1.9B | ||
| Q4 24 | $9.4M | $2.1B | ||
| Q3 24 | $11.3M | $2.1B | ||
| Q2 24 | $11.9M | $1.9B | ||
| Q1 24 | $12.5M | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-916.9K | $192.7M |
| 自由现金流经营现金流 - 资本支出 | — | $188.1M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | — | $681.9M |
8季度趋势，按日历期对齐
经营现金流ISPCMEDP
| Q4 25 | $-916.9K | $192.7M | ||
| Q3 25 | $-2.0M | $246.2M | ||
| Q2 25 | $-192.2K | $148.5M | ||
| Q1 25 | $-1.1M | $125.8M | ||
| Q4 24 | $-3.6M | $190.7M | ||
| Q3 24 | $-1.1M | $149.1M | ||
| Q2 24 | $-1.5M | $116.4M | ||
| Q1 24 | $-2.1M | $152.7M |
自由现金流ISPCMEDP
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | $-3.6M | $183.0M | ||
| Q3 24 | $-1.1M | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | $-2.1M | $147.2M |
自由现金流率ISPCMEDP
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | -242.7% | 34.1% | ||
| Q3 24 | -41.1% | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | -90.9% | 28.8% |
资本支出强度ISPCMEDP
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | 0.5% | 1.4% | ||
| Q3 24 | 0.5% | 2.0% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.4% | 1.1% |
现金转化率ISPCMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISPC
暂无分部数据
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
